This inventor holds 1 USPTO granted patent. Top assignee: Academia Sinica. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations of Chan-Hsien Yeh in Neural Progenitor Cell Research
Introduction
Chan-Hsien Yeh is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of neuroscience through his innovative research and patents. His work focuses on the development of methods and kits for producing induced embryonic neural progenitor cells, which have important implications for treating neurological diseases.
Latest Patents
One of Chan-Hsien Yeh's notable patents is titled "Kit and method for producing induced embryonic neural progenitors." This patent discloses kits that comprise transcription factors for inducing fibroblast cells into induced embryonic neural progenitor cells. These induced cells are capable of differentiating into various types of neural cells, including astrocytes, oligodendrocytes, and neurons. The patent also highlights the uses of the kit as a platform for selecting drug candidates to treat neurological diseases. Chan-Hsien Yeh holds 1 patent in this area.
Career Highlights
Chan-Hsien Yeh is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work at Academia Sinica has allowed him to collaborate with other leading researchers in the field, further advancing the understanding of neural progenitor cells and their potential applications in medicine.
Collaborations
Some of Chan-Hsien Yeh's notable coworkers include Hung-Chih Kuo and Ching-Yu Chuang. Their collaborative efforts contribute to the innovative research being conducted at Academia Sinica.
Conclusion
Chan-Hsien Yeh's contributions to the field of neuroscience through his patent on induced embryonic neural progenitor cells demonstrate his commitment to advancing medical science. His work has the potential to pave the way for new treatments for neurological diseases, showcasing the importance of innovation in research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
